ShockWave Medical (SWAV) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

SWAV Stock Forecast


ShockWave Medical stock forecast is as follows: an average price target of $258.17 (represents a -22.88% downside from SWAV’s last price of $334.75) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.

SWAV Price Target


The average price target for ShockWave Medical (SWAV) is $258.17 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $360.00 to $175.00. This represents a potential -22.88% downside from SWAV's last price of $334.75.

SWAV Analyst Ratings


Hold

According to 10 Wall Street analysts, ShockWave Medical's rating consensus is 'Hold'. The analyst rating breakdown for SWAV stock is 0 'Strong Buy' (0.00%), 1 'Buy' (10.00%), 8 'Hold' (80.00%), 1 'Sell' (10.00%), and 0 'Strong Sell' (0.00%).

ShockWave Medical Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 05, 2024William PlovanicJohnson Rice$335.00$325.482.92%0.07%
Apr 02, 2024Adam MaederPiper Sandler$360.00$320.5112.32%7.54%
Jan 06, 2023-Morgan Stanley$224.00$208.177.60%-33.08%
Aug 29, 2022-Piper Sandler$338.00$304.4411.02%0.97%
Aug 09, 2022-Morgan Stanley$255.00$258.93-1.52%-23.82%
Aug 09, 2022-Wells Fargo$255.00$221.7714.98%-23.82%
Aug 09, 2022-Piper Sandler$278.00$221.7725.36%-16.95%
Jul 15, 2022-Morgan Stanley$201.00$209.90-4.24%-39.96%
May 10, 2022-Morgan Stanley$180.00$133.3934.94%-46.23%
May 10, 2022-Wells Fargo$176.00$115.9151.84%-47.42%
Row per page
Go to

The latest ShockWave Medical stock forecast, released on Apr 05, 2024 by William Plovanic from Johnson Rice, set a price target of $335.00, which represents a 2.92% increase from the stock price at the time of the forecast ($325.48), and a 0.07% increase from SWAV last price ($334.75).

ShockWave Medical Price Target by Period


1M3M12M
# Anlaysts--2
Avg Price Target--$347.50
Last Closing Price$334.75$334.75$334.75
Upside/Downside-100.00%-100.00%3.81%

In the current month, the average price target of ShockWave Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ShockWave Medical's last price of $334.75. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
May 09, 2024Wells FargoEqual-WeightEqual-WeightHold
Apr 08, 2024Morgan StanleyOverweightEqual-WeightDowngrade
Apr 08, 2024Johnson RiceMarket PerformNeutralDowngrade
Apr 05, 2024Johnson RiceHoldMarket PerformDowngrade
Apr 05, 2024Johnson Rice-HoldDowngrade
Apr 05, 2024Piper SandlerOverweightNeutralDowngrade
Apr 05, 2024NeedhamBuyHoldDowngrade
Apr 04, 2024Wolfe Research-Peer PerformDowngrade
Mar 27, 2024Piper SandlerOverweightOverweightHold
Oct 24, 2023NeedhamBuyBuyHold
Row per page
Go to

ShockWave Medical's last stock rating was published by Wells Fargo on May 09, 2024. The company gave SWAV a "Equal-Weight" rating, the same as its previous rate.

ShockWave Medical Financial Forecast


ShockWave Medical Revenue Forecast

Dec 26Oct 26Jul 26Mar 26Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19
Revenue------------$202.98M--$161.07M$144.03M--$93.63M$84.18M--$31.90M$22.72M--$15.20M$14.31M-
Avg Forecast$371.09M$337.78M$325.77M$299.21M$312.84M$287.07M$278.96M$256.28M$253.19M$232.20M$227.06M$207.67M$199.43M$184.72M$173.84M$147.30M$143.18M$123.96M$107.51M$86.41M$75.43M$61.21M$45.22M$29.90M$20.16M$14.68M$8.35M$14.17M$13.47M$10.43M
High Forecast$371.09M$337.78M$325.77M$299.21M$312.84M$287.07M$278.96M$256.28M$253.19M$232.20M$230.18M$207.68M$200.00M$187.99M$173.84M$147.30M$143.18M$123.96M$107.51M$86.41M$75.43M$61.21M$45.22M$29.90M$20.16M$14.68M$8.35M$14.17M$13.47M$10.43M
Low Forecast$371.09M$337.78M$325.77M$299.21M$312.84M$287.07M$278.96M$256.28M$253.19M$232.20M$225.28M$207.66M$199.10M$182.70M$173.84M$147.30M$143.18M$123.96M$107.51M$86.41M$75.43M$61.21M$45.22M$29.90M$20.16M$14.68M$8.35M$14.17M$13.47M$10.43M
# Analysts2222111122436105544445555555544
Surprise %------------1.02%--1.09%1.01%--1.08%1.12%--1.07%1.13%--1.07%1.06%-

ShockWave Medical's average Quarter revenue forecast for Mar 24 based on 3 analysts is $207.67M, with a low forecast of $207.66M, and a high forecast of $207.68M. SWAV's average Quarter revenue forecast represents a 2.31% increase compared to the company's last Quarter revenue of $202.98M (Dec 23).

ShockWave Medical EBITDA Forecast

Dec 26Oct 26Jul 26Mar 26Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19
# Analysts2222111122436105544445555555544
EBITDA------------$46.36M--$41.37M$45.62M--$16.73M$15.02M--$-22.12M$-296.87K--$-17.68M$-13.85M-
Avg Forecast$-110.63M$-100.70M$-97.12M$-89.20M$-93.27M$-85.59M$-83.17M$-76.40M$-75.48M$-69.23M$-67.70M$18.68M$-59.46M$-55.07M$-51.83M$16.98M$42.47M$-36.96M$-32.05M$15.44M$-22.49M$-18.25M$-13.48M$-11.90M$-6.01M$-4.38M$-2.49M$-14.07M$-4.02M$-3.11M
High Forecast$-110.63M$-100.70M$-97.12M$-89.20M$-93.27M$-85.59M$-83.17M$-76.40M$-75.48M$-69.23M$-67.17M$22.42M$-59.36M$-54.47M$-51.83M$20.38M$50.97M$-36.96M$-32.05M$18.53M$-22.49M$-18.25M$-13.48M$-9.52M$-6.01M$-4.38M$-2.49M$-11.26M$-4.02M$-3.11M
Low Forecast$-110.63M$-100.70M$-97.12M$-89.20M$-93.27M$-85.59M$-83.17M$-76.40M$-75.48M$-69.23M$-68.62M$14.94M$-59.63M$-56.05M$-51.83M$13.59M$33.98M$-36.96M$-32.05M$12.35M$-22.49M$-18.25M$-13.48M$-14.27M$-6.01M$-4.38M$-2.49M$-16.89M$-4.02M$-3.11M
Surprise %-------------0.78%--2.44%1.07%--1.08%-0.67%--1.86%0.05%--1.26%3.45%-

3 analysts predict SWAV's average Quarter EBITDA for Mar 24 to be $18.68M, with a high of $22.42M and a low of $14.94M. This is -59.70% lower than ShockWave Medical's previous annual EBITDA (Dec 23) of $46.36M.

ShockWave Medical Net Income Forecast

Dec 26Oct 26Jul 26Mar 26Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19
# Analysts2222111122436105544445555555544
Net Income------------$44.30M--$39.13M$140.91M--$14.52M$12.94M--$-23.60M$-15.87K--$-18.77M$-14.74M-
Avg Forecast$79.75M$71.53M$68.63M$61.49M$68.60M$62.06M$59.63M$54.59M$58.07M$49.69M$45.16M$16.21M$34.25M$29.98M$31.87M$14.74M$36.61M$25.72M$17.06M$13.40M$3.28M$-2.19M$-15.33M$-12.69M$-16.30M$-21.28M$-23.91M$-14.94M$-19.73M$-19.62M
High Forecast$79.75M$71.53M$68.63M$61.49M$68.60M$62.06M$59.63M$54.59M$58.07M$49.69M$55.07M$19.45M$43.55M$36.81M$31.87M$17.68M$43.93M$25.72M$17.06M$16.08M$3.28M$-2.19M$-15.33M$-10.15M$-16.30M$-21.28M$-23.91M$-11.95M$-19.73M$-19.62M
Low Forecast$79.75M$71.53M$68.63M$61.49M$68.60M$62.06M$59.63M$54.59M$58.07M$49.69M$42.59M$12.97M$30.90M$24.29M$31.87M$11.79M$29.29M$25.72M$17.06M$10.72M$3.28M$-2.19M$-15.33M$-15.23M$-16.30M$-21.28M$-23.91M$-17.93M$-19.73M$-19.62M
Surprise %------------1.29%--2.66%3.85%--1.08%3.94%--1.86%0.00%--1.26%0.75%-

ShockWave Medical's average Quarter net income forecast for Mar 24 is $16.21M, with a range of $12.97M to $19.45M. SWAV's average Quarter net income forecast represents a -63.41% decrease compared to the company's last Quarter net income of $44.30M (Dec 23).

ShockWave Medical SG&A Forecast

Dec 26Oct 26Jul 26Mar 26Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19
# Analysts2222111122436105544445555555544
SG&A------------$92.06M--$73.22M$60.38M--$48.35M$42.82M--$31.22M$23.07M--$16.64M$14.05M-
Avg Forecast$271.80M$247.41M$238.61M$219.16M$229.14M$210.26M$204.32M$187.71M$185.45M$170.07M$166.31M$53.97M$146.07M$135.29M$127.33M$49.07M$121.12M$90.80M$78.75M$44.61M$55.25M$44.83M$33.12M$16.79M$14.76M$10.75M$6.11M$13.24M$9.87M$7.64M
High Forecast$271.80M$247.41M$238.61M$219.16M$229.14M$210.26M$204.32M$187.71M$185.45M$170.07M$168.60M$64.77M$146.49M$137.70M$127.33M$58.88M$145.34M$90.80M$78.75M$53.53M$55.25M$44.83M$33.12M$20.15M$14.76M$10.75M$6.11M$15.89M$9.87M$7.64M
Low Forecast$271.80M$247.41M$238.61M$219.16M$229.14M$210.26M$204.32M$187.71M$185.45M$170.07M$165.01M$43.18M$145.83M$133.82M$127.33M$39.25M$96.90M$90.80M$78.75M$35.68M$55.25M$44.83M$33.12M$13.43M$14.76M$10.75M$6.11M$10.59M$9.87M$7.64M
Surprise %------------0.63%--1.49%0.50%--1.08%0.78%--1.86%1.56%--1.26%1.42%-

ShockWave Medical's average Quarter SG&A projection for Mar 24 is $53.97M, based on 3 Wall Street analysts, with a range of $43.18M to $64.77M. The forecast indicates a -41.37% fall compared to SWAV last annual SG&A of $92.06M (Dec 23).

ShockWave Medical EPS Forecast

Dec 26Oct 26Jul 26Mar 26Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19
# Analysts2222111122436105544445555555544
EPS------------$1.16--$1.07$3.89--$0.41$0.37--$-0.68$-0.00--$-0.59$-0.49-
Avg Forecast$2.07$1.86$1.78$1.60$1.78$1.61$1.55$1.42$1.51$1.29$1.17$0.99$0.89$0.78$0.83$0.79$1.01$0.67$0.44$0.18$0.09$-0.06$-0.40$-0.45$-0.42$-0.55$-0.62$-0.49$-0.51$-0.51
High Forecast$2.07$1.86$1.78$1.60$1.78$1.61$1.55$1.42$1.51$1.29$1.43$0.99$1.13$0.96$0.83$0.79$1.01$0.67$0.44$0.18$0.09$-0.06$-0.40$-0.45$-0.42$-0.55$-0.62$-0.49$-0.51$-0.51
Low Forecast$2.07$1.86$1.78$1.60$1.78$1.61$1.55$1.42$1.51$1.29$1.11$0.99$0.80$0.63$0.83$0.79$1.01$0.67$0.44$0.18$0.09$-0.06$-0.40$-0.45$-0.42$-0.55$-0.62$-0.49$-0.51$-0.51
Surprise %------------1.30%--1.35%3.86%--2.23%4.34%--1.52%0.00%--1.20%0.96%-

According to 3 Wall Street analysts, ShockWave Medical's projected average Quarter EPS for Mar 24 is $0.99, with a low estimate of $0.99 and a high estimate of $0.99. This represents a -14.72% decrease compared to SWAV previous annual EPS of $1.16 (Dec 23).

ShockWave Medical Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
OMOutset Medical$0.62$11.001674.19%Buy
TNDMTandem Diabetes Care$32.85$81.22147.25%Buy
ALGNAlign$210.78$421.0099.73%Buy
TMDXTransMedics Group$84.97$126.7549.17%Buy
NARIInari Medical$48.93$66.1135.11%Buy
EWEdwards Lifesciences$66.47$88.0432.45%Buy
INSPInspire Medical Systems$192.71$238.0023.50%Buy
DXCMDexCom$69.70$81.3616.73%Buy
PODDInsulet$237.44$270.9314.10%Buy
MASIMasimo$147.39$160.208.69%Buy
PENPenumbra$229.51$224.85-2.03%Buy
CLPTClearPoint Neuro$12.74$12.00-5.81%Buy
SYKStryker$366.90$317.96-13.34%Buy
SWAVShockWave Medical$334.75$258.17-22.88%Hold

SWAV Forecast FAQ


No, according to 10 Wall Street analysts, ShockWave Medical (SWAV) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 10.00% of SWAV's total ratings.

ShockWave Medical (SWAV) average price target is $258.17 with a range of $175 to $360, implying a -22.88% from its last price of $334.75. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for SWAV stock, the company can go down by -22.88% (from the last price of $334.75 to the average price target of $258.17), up by 7.54% based on the highest stock price target, and down by -47.72% based on the lowest stock price target.

SWAV's average twelve months analyst stock price target of $258.17 does not support the claim that ShockWave Medical can reach $500 in the near future.

ShockWave Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.14B (high $1.14B, low $1.14B), average EBITDA is $-338M (high $-338M, low $-338M), average net income is $244.88M (high $244.88M, low $244.88M), average SG&A $831.44M (high $831.44M, low $831.44M), and average EPS is $6.37 (high $6.37, low $6.37). SWAV's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.33B (high $1.33B, low $1.33B), average EBITDA is $-398M (high $-398M, low $-398M), average net income is $281.41M (high $281.41M, low $281.41M), average SG&A $976.98M (high $976.98M, low $976.98M), and average EPS is $7.31 (high $7.31, low $7.31).

Based on ShockWave Medical's last annual report (Dec 2023), the company's revenue was $730.23M, beating the average analysts forecast of $705.28M by 3.54%. Apple's EBITDA was $169.45M, missing the average prediction of $-149M by -213.44%. The company's net income was $147.28M, beating the average estimation of $110.83M by 32.88%. Apple's SG&A was $330.1M, missing the average forecast of $457.76M by -27.89%. Lastly, the company's EPS was $3.85, beating the average prediction of $3.29 by 16.95%. In terms of the last quarterly report (Dec 2023), ShockWave Medical's revenue was $202.98M, beating the average analysts' forecast of $199.43M by 1.78%. The company's EBITDA was $46.36M, missing the average prediction of $-59.457M by -177.97%. ShockWave Medical's net income was $44.3M, beating the average estimation of $34.25M by 29.37%. The company's SG&A was $92.06M, missing the average forecast of $146.07M by -36.98%. Lastly, the company's EPS was $1.16, beating the average prediction of $0.89 by 30.31%